XENE

XEN007 (Calcium Channel Inhibitor)

Childhood Absence Epilepsy

Phase 2 (Top-line Data)

Exp Date

Middle of 2021

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: XEN007 for Childhood Absence Epilepsy 



WHAT IS THE CATALYST EVENT?

  • Phase 2 (Top-line Data)


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?


PRIOR DATA/EVENTS

PRESS RELEASE

MECHANISM OF ACTION

  • XEN007 (active ingredient flunarizine) is a CNS-acting calcium channel modulator that modulates Cav2.1 and T-type calcium channels. Other reported mechanisms include dopamine, histamine and serotonin inhibition. Flunarizine is available in certain countries outside of the United States and has been reported to have clinical benefit in treating migraine and other neurological disorders.

Updated by HC

XENE, XEN007 (Calcium Channel Inhibitor), flunarizine, childhood absence epilepsy, CAE

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon